{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:54:06Z","timestamp":1791910446091,"version":"4.3.4"},"reference-count":264,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118303","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:14:26Z","timestamp":1785770066000},"page":"118303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Deciphering the colorectal tumor microenvironment: Interactions and targets for effective therapy"],"prefix":"10.1016","volume":"253","author":[{"given":"Jingming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengqiu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0005","first-page":"E499","article-title":"Global disparities in colorectal cancer: unveiling the present landscape of incidence and mortality rates, analyzing geographical variances, and assessing the human development index","volume":"65","author":"Darmadi","year":"2025","journal-title":"J. Prev. Med. Hyg."},{"key":"10.1016\/j.bcp.2026.118303_b0010","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, T.B. Kratzer, N.S. Wagle, et al. Cancer statistics, 2026. CA: A Cancer Journal for Clinicians. 2026 2026\/01\/01; 76(1): e70043.","DOI":"10.3322\/caac.70043"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","article-title":"Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data","volume":"26","author":"Sung","year":"2025","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0020","first-page":"184","article-title":"Surgery for colorectal cancer-trends, developments, and future perspectives","volume":"32","author":"Rentsch","year":"2016","journal-title":"Viszeralmedizin"},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.radonc.2018.06.035","article-title":"Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review","volume":"129","author":"Petrelli","year":"2018","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/2212697X05666180905094942","article-title":"Oxaliplatin for colorectal cancer therapy: a review","volume":"5","author":"Sharma","year":"2018","journal-title":"Clin. Cancer Drugs."},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/ph14070639","article-title":"Anticancer drugs for intra-arterial treatment of colorectal cancer liver metastases: In-vitro screening after short exposure time","volume":"14","author":"Fohlen","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0040","first-page":"81","article-title":"Role of first-line anti\u2013epidermal growth factor receptor therapy compared with anti\u2013vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials","volume":"14","author":"Khattak","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b0050","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers11081172","article-title":"The tumor microenvironment in colorectal cancer therapy","volume":"11","author":"Pedrosa","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-021-00738-0","article-title":"Immune regulation in the tumor microenvironment and its relevance in cancer therapy","volume":"19","author":"Zou","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b0060","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00262-025-04173-2","article-title":"The single-cell atlas of colorectal cancer reveals cellular heterogeneity and key molecular features of the tumor immune microenvironment","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b0070","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1002\/ctm2.422","article-title":"Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer","volume":"11","author":"Mei","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.118303_b0075","doi-asserted-by":"crossref","first-page":"e1516","DOI":"10.1002\/ctm2.1516","article-title":"The molecular classification of cancer-associated fibroblasts on a pan-cancer single-cell transcriptional atlas","volume":"13","author":"Chen","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/ijms19010299","article-title":"\u201cVessels in the storm\u201d: searching for prognostic and predictive angiogenic factors in colorectal cancer","volume":"19","author":"Angelucci","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b0085","first-page":"769","article-title":"The current role of dendritic cells in the progression and treatment of colorectal cancer","volume":"21","author":"Zhang","year":"2024","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0090","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","article-title":"Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer","volume":"71","author":"Tosolini","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b0095","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nm.4086","article-title":"Two FOXP3+ CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers","volume":"22","author":"Saito","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0100","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1724763","article-title":"Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer","volume":"9","author":"Yamaguchi","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2026.118303_b0105","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3389\/fimmu.2020.01526","article-title":"Myeloid-derived suppressor cells in colorectal cancer","volume":"11","author":"Sieminska","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b0110","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00384-020-03593-z","article-title":"Tumor-associated macrophage infiltration and prognosis in colorectal cancer: systematic review and meta-analysis","volume":"35","author":"Li","year":"2020","journal-title":"Int. J. Colorectal Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0115","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jso.24523","article-title":"The prognostic value of neutrophil\u2010to\u2010lymphocyte ratio in colorectal cancer: a systematic review","volume":"115","author":"Haram","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.bcp.2026.118303_b0120","article-title":"Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118303_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1051330","article-title":"Role of microbes in colorectal cancer therapy: cross-talk between the microbiome and tumor microenvironment","volume":"13","author":"Xia","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b0130","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s43018-024-00807-z","article-title":"Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms","volume":"5","author":"Chu","year":"2024","journal-title":"Nat Cancer."},{"key":"10.1016\/j.bcp.2026.118303_b0135","doi-asserted-by":"crossref","unstructured":"N. Lamers-Kok, D. Panella, A.-M. Georgoudaki, et al., Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J. Hematol. Oncol., 2022; 15(1): 164.","DOI":"10.1186\/s13045-022-01382-5"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0140","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2046931","article-title":"Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer","volume":"11","author":"Ducoin","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2026.118303_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.778329","article-title":"Colorectal cancer-associated immune exhaustion involves T and B lymphocytes and conventional NK cells and correlates with a shorter overall survival","volume":"12","author":"Sorrentino","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-71085-9","article-title":"Tumor-infiltrating immature innate lymphoid cells in colorectal cancer are biased toward ILC1\/tissue-resident NK cell differentiation","volume":"17","author":"Marchalot","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118303_b0155","doi-asserted-by":"crossref","unstructured":"M. Della Chiesa, C. Setti, C. Giordano, et al., NK Cell-based immunotherapy in colorectal cancer. Vaccines (Basel). 2022 Jun 28; 10(7).","DOI":"10.3390\/vaccines10071033"},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b0160","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184036","article-title":"Cxcr3 promotes protection from colorectal cancer liver metastasis by driving NK cell infiltration and plasticity","volume":"135","author":"Russo","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118303_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109944","article-title":"Exploring the effect of polyamines on NK cell function in colorectal cancer process based on glycolysis","volume":"117","author":"He","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12935-024-03520-0","article-title":"Acid affairs in anti-tumour immunity","volume":"24","author":"Cappellesso","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.118303_b0175","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.3389\/fimmu.2019.02584","article-title":"Mass cytometry reveals a sustained reduction in CD16(+) natural killer cells following chemotherapy in colorectal cancer patients","volume":"10","author":"Shinko","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118303_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737311","article-title":"The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies","volume":"12","author":"Baysal","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118303_b0185","doi-asserted-by":"crossref","unstructured":"N.B. Volz, D.L. Hanna, S. Stintzing, et al., Polymorphisms within immune regulatory pathways predict cetuximab efficacy and survival in metastatic colorectal cancer patients. Cancers (Basel). 2020 Oct 13; 12(10).","DOI":"10.3390\/cancers12102947"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0190","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1950264","article-title":"Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors","volume":"13","author":"Wingert","year":"2021","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b0195","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-24-1991","article-title":"First-in-human phase I study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors","volume":"31","author":"El-Khoueiry","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118303_b0200","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK cell-based immune checkpoint inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118303_b0205","doi-asserted-by":"crossref","unstructured":"S.P. Patel, T. Alonso-Gordoa, S. Banerjee, et al., Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. J Immunother Cancer. 2024 Feb 2; 12(2).","DOI":"10.1136\/jitc-2023-007340"},{"key":"10.1016\/j.bcp.2026.118303_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110207","article-title":"Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8(+) T cells showed synergistic effects on improved disease-free survival in treatment-na\u00efve CRC patients","volume":"119","author":"Meyiah","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118303_b0215","first-page":"7(7)","article-title":"Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer","volume":"8","author":"Masuda","year":"2022","journal-title":"JCI Insight"},{"issue":"18","key":"10.1016\/j.bcp.2026.118303_b0220","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41421-023-00605-4","article-title":"Single cell dynamics of tumor specificity vs bystander activity in CD8(+) T cells define the diverse immune landscapes in colorectal cancer","volume":"9","author":"Borr\u00e0s","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.bcp.2026.118303_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1057292","article-title":"Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided \u201cimmune-hot\u201d colorectal cancers","volume":"14","author":"Talhouni","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109422","article-title":"Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts","volume":"36","author":"Rodriguez","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118303_b0240","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3389\/fimmu.2019.01884","article-title":"The crohn's-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer","volume":"10","author":"Maoz","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-024-00533-w","article-title":"Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer","volume":"8","author":"Wang","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b0250","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.21873\/anticanres.14657","article-title":"Tertiary lymphoid structures in colorectal cancer liver metastases: association with immunological and clinical parameters and chemotherapy response","volume":"40","author":"Ahmed","year":"2020","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.bcp.2026.118303_b0255","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.immuni.2021.11.003","article-title":"Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer","volume":"54","author":"Overacre-Delgoffe","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0260","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2300520","article-title":"Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity","volume":"13","author":"Lizarralde-Guerrero","year":"2024","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0265","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000881","article-title":"Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer","volume":"8","author":"Mo","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b0270","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0275","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41423-021-00634-7","article-title":"HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy","volume":"18","author":"Anderson","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118303_b0280","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118303_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.688961","article-title":"TIGIT induces (CD3+) T cell dysfunction in colorectal cancer by inhibiting glucose metabolism","volume":"12","author":"Shao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118303_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.113996","article-title":"Developing oxaliplatin and IL-15 Co-carried gels as drug depots to enable triple-interlocked combination therapy for colorectal cancer","volume":"241","author":"Jiang","year":"2024","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"23","key":"10.1016\/j.bcp.2026.118303_b0295","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bcp.2026.118303_b0300","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.bcp.2026.118303_b0305","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118303_b0310","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","article-title":"A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer","volume":"169","author":"Kim","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b0315","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0320","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118303_b0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04380-z","article-title":"Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial","author":"Melero","year":"2026","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b0330","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41416-019-0559-6","article-title":"Intratumoural-infiltrating CD4\u2009+\u2009and FOXP3\u2009+\u2009T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer","volume":"121","author":"Kuwahara","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2026.118303_b0335","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/bjc.2014.161","article-title":"The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues","volume":"110","author":"Ling","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b0340","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nm.4086","article-title":"Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers","volume":"22","author":"Saito","year":"2016","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0345","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","article-title":"CD4+ T cells in cancer","volume":"4","author":"Speiser","year":"2023","journal-title":"Nature Cancer."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0350","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bcp.2026.118303_b0355","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2159-8290.CD-15-0447","article-title":"Regulatory T-cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis","volume":"5","author":"Geis","year":"2015","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0360","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","article-title":"Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer","volume":"71","author":"Tosolini","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118303_b0365","article-title":"The role of Treg cells in colorectal cancer and the immunotherapy targeting Treg cells","volume":"16","author":"Yu","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0370","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.trecan.2022.12.007","article-title":"T follicular helper cells in cancer","volume":"9","author":"Guti\u00e9rrez-Melo","year":"2023","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b0375","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.bcp.2026.118303_b0380","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118303_b0385","doi-asserted-by":"crossref","unstructured":"M.J. Overman, F. Gelsomino, M. Aglietta, et al., Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J. Immunother. Cancer. 2024; 12(5).","DOI":"10.1136\/jitc-2023-008689"},{"issue":"3_suppl","key":"10.1016\/j.bcp.2026.118303_b0390","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JCO.2021.39.3_suppl.79","article-title":"Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy","volume":"39","author":"Morris","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b0395","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-23-3964","article-title":"Clinical challenges of consensus molecular subtype CMS4 colon cancer in the era of precision medicine","volume":"30","author":"Mouillet-Richard","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0400","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2021.11.037","article-title":"The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis","volume":"162","author":"Kobayashi","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003591","article-title":"Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S","volume":"10","author":"Harryvan","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl 2 2","key":"10.1016\/j.bcp.2026.118303_b0410","first-page":"S18","article-title":"Cancer-associated fibroblast (CAF) secretomes-induced epithelial-mesenchymal transition on HT-29 colorectal carcinoma cells associated with hepatocyte growth factor (HGF) signalling","volume":"71","author":"Wanandi","year":"2021","journal-title":"J. Pak. Med. Assoc."},{"key":"10.1016\/j.bcp.2026.118303_b0415","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3389\/fonc.2020.01747","article-title":"Increased RAB31 expression in cancer-associated fibroblasts promotes colon cancer progression through HGF-MET signaling","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118303_b0420","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12935-019-0914-y","article-title":"Human colorectal cancer-derived carcinoma associated fibroblasts promote CD44-mediated adhesion of colorectal cancer cells to endothelial cells by secretion of HGF","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0425","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/1078-0432.CCR-10-0568","article-title":"HGF rescues colorectal cancer cells from EGFR inhibition via MET activation","volume":"17","author":"Liska","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b0430","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s00432-021-03872-4","article-title":"Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers","volume":"148","author":"Kim","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0435","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00018-023-05071-5","article-title":"Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer","volume":"81","author":"Jones","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b0440","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1007\/s10637-020-00928-z","article-title":"A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment","volume":"38","author":"Delord","year":"2020","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0445","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbrc.2017.03.039","article-title":"FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression","volume":"487","author":"Chen","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110701","article-title":"Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling","volume":"27","author":"Leonard","year":"2024","journal-title":"Iscience"},{"issue":"46","key":"10.1016\/j.bcp.2026.118303_b0455","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118303_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117049","article-title":"Stromal reprogramming: a target for tumor therapy","volume":"239","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.118303_b0465","doi-asserted-by":"crossref","unstructured":"T.J. Harryvan, S. Abudukelimu, I. Stouten, et al., TGF\u03b2 signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancer. iScience. 2025 Nov 21; 28(11): 113696.","DOI":"10.1016\/j.isci.2025.113696"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0470","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-025-03297-8","article-title":"Extracellular matrix stiffness regulates colorectal cancer progression via HSF4","volume":"44","author":"Wang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0475","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/path.6033","article-title":"Cancer-associated fibroblasts potentiate colorectal cancer progression by crosstalk of the IGF2-IGF1R and Hippo-YAP1 signaling pathways","volume":"259","author":"Zhang","year":"2023","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0480","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13058-022-01548-6","article-title":"Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction","volume":"24","author":"Mir","year":"2022","journal-title":"Breast Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b0485","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1158\/2767-9764.CRC-22-0194","article-title":"Bintrafusp alfa, an anti-PD-L1: TGF-\u03b2 trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer","volume":"2","author":"Morris","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0490","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40199-023-00474-y","article-title":"Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer","volume":"31","author":"Binabaj","year":"2023","journal-title":"DARU J. Pharma. Sci."},{"issue":"7_Supplement","key":"10.1016\/j.bcp.2026.118303_b0495","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1538-7445.AM2026-1562","article-title":"Abstract 1562: rewiring the immune-excluded tumor microenvironment: Vactosertib\/anti-PD-1\/VEGF inhibitor triplet therapy reinstates antitumor immunity in CRC","volume":"86","author":"Kim","year":"2026","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.bcp.2026.118303_b0500","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-23-3567","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity from a phase I study of simlukafusp alfa (FAP-IL2v) in advanced\/metastatic solid tumors","volume":"30","author":"Steeghs","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118303_b0505","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jss.2025.11.050","article-title":"Impact of pirfenidone administration routes on colon anastomosis and healing in rats","volume":"317","author":"Duran","year":"2026","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0510","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41420-026-02945-y","article-title":"Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K\/AKT\/CSF1-CSF1R axis","volume":"12","author":"Liang","year":"2026","journal-title":"Cell Death Discov."},{"issue":"10","key":"10.1016\/j.bcp.2026.118303_b0515","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201982RRR","article-title":"CXCL8 induces M2 macrophage polarization and inhibits CD8(+) T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer","volume":"37","author":"Shao","year":"2023","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0520","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41420-020-00350-7","article-title":"Macrophages produce and functionally respond to interleukin-34 in colon cancer","volume":"6","author":"Franz\u00e8","year":"2020","journal-title":"Cell Death Discov."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0525","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41419-021-03426-z","article-title":"Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer","volume":"12","author":"Klemke","year":"2021","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b0530","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1170264","article-title":"Extracellular HSP110 skews macrophage polarization in colorectal cancer","volume":"5","author":"Berthenet","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0535","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12964-020-00557-2","article-title":"Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression","volume":"18","author":"Liu","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bcp.2026.118303_b0540","doi-asserted-by":"crossref","first-page":"7343","DOI":"10.2147\/IJN.S499381","article-title":"Cancer-derived exosomal LINC01615 induces M2 polarization of tumor-associated macrophages via RBMX-EZH2 axis to promote colorectal cancer progression","volume":"20","author":"Li","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bcp.2026.118303_b0545","doi-asserted-by":"crossref","unstructured":"Z. Sun, Y. Xu, B. Shao, et al. Exosomal circPOLQ promotes macrophage M2 polarization via activating IL-10\/STAT3 axis in a colorectal cancer model. J. Immunother. Cancer. 2024; 12(5).","DOI":"10.1136\/jitc-2023-008491"},{"issue":"33","key":"10.1016\/j.bcp.2026.118303_b0550","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.2174\/0929867331666230703143907","article-title":"The Metformin immunoregulatory actions in tumor suppression and normal tissues protection","volume":"31","author":"Gupta","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b0555","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00384-020-03593-z","article-title":"Tumor-associated macrophage infiltration and prognosis in colorectal cancer: systematic review and meta-analysis","volume":"35","author":"Li","year":"2020","journal-title":"Int. J. Colorectal Dis."},{"issue":"5","key":"10.1016\/j.bcp.2026.118303_b0560","doi-asserted-by":"crossref","first-page":"984","DOI":"10.7150\/ijbs.29836","article-title":"Elevated CD163(+)\/CD68(+) ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer","volume":"15","author":"Yang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0565","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s13402-024-00926-w","article-title":"The prognostic effect of tumor-associated macrophages in stage I-III colorectal cancer depends on T cell infiltration","volume":"47","author":"Majid","year":"2024","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"10.1016\/j.bcp.2026.118303_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101346","article-title":"Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery","volume":"17","author":"Siemi\u0144ska","year":"2022","journal-title":"Transl. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118303_b0575","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1494113","article-title":"Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: a meta-analysis of 40 studies","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"23","key":"10.1016\/j.bcp.2026.118303_b0580","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-17-1283","article-title":"The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6","volume":"23","author":"Yin","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0585","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41419-017-0176-3","article-title":"Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6\/JAK2\/STAT3 signaling","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0590","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4143\/crt.2017.613","article-title":"Tumor-associated macrophages derived TGF-\u03b2\u2012induced epithelial to mesenchymal transition in colorectal cancer cells through smad2, 3-4\/snail signaling pathway","volume":"51","author":"Cai","year":"2019","journal-title":"Cancer Res. Treatment: Off. J. Korean Cancer Assoc."},{"key":"10.1016\/j.bcp.2026.118303_b0595","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.2147\/OTT.S336548","article-title":"M2-type macrophages induce tregs generation by activating the TGF-\u03b2\/Smad signalling pathway to promote colorectal cancer development","author":"Ma","year":"2021","journal-title":"Onco Targets Ther."},{"issue":"16","key":"10.1016\/j.bcp.2026.118303_b0600","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","article-title":"Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses","volume":"64","author":"Rodriguez","year":"2004","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0605","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5673","article-title":"Myeloid\u2013derived suppressor cells: key immunosuppressive regulators and therapeutic targets in colorectal cancer (review)","volume":"65","author":"Zeng","year":"2024","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0610","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","article-title":"CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation","volume":"44","author":"Kumar","year":"2016","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b0615","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","article-title":"Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells","volume":"182","author":"Corzo","year":"2009","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118303_b0620","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","article-title":"Dependency of colorectal cancer on a TGF-\u03b2-driven program in stromal cells for metastasis initiation","volume":"22","author":"Calon","year":"2012","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.bcp.2026.118303_b0625","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.3390\/ijms22168470","article-title":"Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0630","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1158\/0008-5472.CAN-25-0079","article-title":"Tumor-associated macrophages produce PGE2 to promote CD8+ T-cell exhaustion and drive resistance to PD-L1 blockade in microsatellite-stable colorectal cancer","volume":"86","author":"Fumet","year":"2026","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0635","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00262-020-02676-8","article-title":"Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer","volume":"70","author":"Min","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.bcp.2026.118303_b0640","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mc.22289","article-title":"LoVo colon cancer cells resistant to oxaliplatin overexpress c\u2010MET and VEGFR\u20101 and respond to VEGF with dephosphorylation of c\u2010MET","volume":"55","author":"Mezquita","year":"2016","journal-title":"Mol. Carcinog."},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062092","article-title":"S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt\/\u03b2-catenin pathway","volume":"8","author":"Duan","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b0650","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.7150\/jca.92588","article-title":"S100A8-mediated inflammatory signaling drives colorectal cancer progression via the CXCL5\/CXCR2 Axis","volume":"15","author":"Chen","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2026.118303_b0655","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.2147\/OTT.S278013","article-title":"Progress in understanding the IL-6\/STAT3 pathway in colorectal cancer","volume":"13","author":"Lin","year":"2020","journal-title":"Onco Targets Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0660","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.celrep.2015.06.024","article-title":"CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function","volume":"12","author":"Chun","year":"2015","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.bcp.2026.118303_b0665","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s41419-021-04166-w","article-title":"TCF4 enhances hepatic metastasis of colorectal cancer by regulating tumor-associated macrophage via CCL2\/CCR2 signaling","volume":"12","author":"Tu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118303_b0670","article-title":"Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer","volume":"6","author":"Chan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b0675","article-title":"Role of HGF\/c\u2010Met in the treatment of colorectal cancer with liver metastasis","volume":"33","author":"Jf","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"14","key":"10.1016\/j.bcp.2026.118303_b0680","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.3390\/ijms22147371","article-title":"CXCL12-CXCR4\/CXCR7 axis in colorectal cancer: therapeutic target in preclinical and clinical studies","volume":"22","author":"Khare","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0685","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12964-024-01771-y","article-title":"IL-1\u03b2 mediates Candida tropicalis-induced immunosuppressive function of MDSCs to foster colorectal cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun. Signaling"},{"key":"10.1016\/j.bcp.2026.118303_b0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661323","article-title":"Tumor NLRP3-derived IL-1\u03b2 drives the IL-6\/STAT3 axis resulting in sustained MDSC-mediated immunosuppression","volume":"12","author":"Tengesdal","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b0695","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41590-024-01755-7","article-title":"IL-23 stabilizes an effector Treg cell program in the tumor microenvironment","volume":"25","author":"Wertheimer","year":"2024","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0700","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3892\/ol.2012.739","article-title":"IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma","volume":"4","author":"Suzuki","year":"2012","journal-title":"Oncol. Lett."},{"issue":"21","key":"10.1016\/j.bcp.2026.118303_b0705","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102950118","article-title":"Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8+ regulatory T cells","volume":"118","author":"Cagnoni","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2026.118303_b0710","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.716055","article-title":"Stromal galectin-1 promotes colorectal cancer cancer-initiating cell features and disease dissemination through SOX9 and \u03b2-catenin: development of niche-based biomarkers","volume":"11","author":"Peng","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0715","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11010-016-2873-0","article-title":"TLR4-mediated galectin-1 production triggers epithelial-mesenchymal transition in colon cancer cells through ADAM10-and ADAM17-associated lactate production","volume":"425","author":"Park","year":"2017","journal-title":"Mol. Cell. Biochem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b0720","first-page":"2402","article-title":"Extracellular galectin-3 facilitates colon cancer cell migration and is related to the epidermal growth factor receptor","volume":"10","author":"Wu","year":"2018","journal-title":"Am. J. Transl. Res."},{"issue":"18","key":"10.1016\/j.bcp.2026.118303_b0725","doi-asserted-by":"crossref","first-page":"14402","DOI":"10.3390\/ijms241814402","article-title":"Knockdown of BAP31 downregulates galectin-3 to inhibit the Wnt\/\u03b2-catenin signaling pathway to modulate 5-FU chemosensitivity and cancer stemness in colorectal cancer","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118303_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116172","article-title":"Astragalus polysaccharide ameliorates CD8+ T cell dysfunction through STAT3\/Gal-3\/LAG3 pathway in inflammation\u2010induced colorectal cancer","volume":"171","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0735","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/biom15010035","article-title":"Targeting invasion: the role of MMP-2 and MMP-9 Inhibition in colorectal cancer therapy","volume":"15","author":"Shoari","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0740","first-page":"CRC40","article-title":"Exosome-derived miRNAs regulate macrophage-colorectal cancer cell cross-talk during aggressive tumor development. Colorectal","volume":"12","author":"Wadhonkar","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.118303_b0745","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omto.2021.02.005","article-title":"M2 macrophage-derived exosomal microRNA-155-5p promotes the immune escape of colon cancer by downregulating ZC3H12B","volume":"20","author":"Ma","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bcp.2026.118303_b0750","first-page":"2021","article-title":"Exosomal miR-183-5p shuttled by M2 polarized tumor-associated macrophage promotes the development of colon cancer via targeting THEM4 mediated PI3K\/AKT and NF-\u03bab pathways [original research]","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0755","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-020-00991-2","article-title":"Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer","volume":"13","author":"Zhao","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"18","key":"10.1016\/j.bcp.2026.118303_b0760","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201901278","article-title":"Granulocytic myeloid\u2010derived suppressor cells promote the stemness of colorectal cancer cells through exosomal S100A9","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.118303_b0765","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2174\/1568026623666230201145909","article-title":"Tumor-associated macrophages (TAMs) in cancer resistance; modulation by natural products","volume":"23","author":"Lafta","year":"2023","journal-title":"Curr. Top. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b0770","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1470729","article-title":"Recruitment of CCR2(+) tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer","volume":"7","author":"Grossman","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0775","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12865-022-00493-5","article-title":"Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb\/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy","volume":"23","author":"Bess","year":"2022","journal-title":"BMC Immunol."},{"key":"10.1016\/j.bcp.2026.118303_b0780","doi-asserted-by":"crossref","first-page":"4(7)","DOI":"10.1172\/jci.insight.126853","article-title":"Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy","volume":"4","author":"Sun","year":"2019","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.bcp.2026.118303_b0785","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005610","article-title":"Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages","volume":"10","author":"Zhu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118303_b0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107126","article-title":"CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer","volume":"202","author":"Lv","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b0795","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1021\/acs.jmedchem.4c00508","article-title":"Discovery of a novel CSF-1R inhibitor with highly improved pharmacokinetic profiles and superior efficacy in colorectal cancer immunotherapy","volume":"67","author":"Lv","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0800","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12951-024-02584-4","article-title":"Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications","volume":"22","author":"Tong","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b0805","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118303_b0810","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","article-title":"Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab","volume":"63","author":"Tobin","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0815","article-title":"First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours","volume":"3","author":"Naing","year":"2024","journal-title":"BMJ Oncol."},{"issue":"14","key":"10.1016\/j.bcp.2026.118303_b0820","article-title":"Multifunctional nanodrug mediates synergistic photodynamic therapy and MDSCs-targeting immunotherapy of colon cancer","volume":"8","author":"Ding","year":"2021","journal-title":"Adv. Sci. (Weinh)."},{"issue":"12","key":"10.1016\/j.bcp.2026.118303_b0825","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0830","first-page":"41","article-title":"Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC","volume":"7","author":"Lin","year":"2017","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0835","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12916-023-03094-0","article-title":"A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy","volume":"21","author":"Chen","year":"2023","journal-title":"BMC Med."},{"issue":"13_Supplement","key":"10.1016\/j.bcp.2026.118303_b0840","doi-asserted-by":"crossref","first-page":"CT089","DOI":"10.1158\/1538-7445.AM2017-CT089","article-title":"Abstract CT089: IPI-549-01-a phase 1\/1b, first-in-human study of IPI-549, a PI3K-\u03b3 inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors","volume":"77","author":"Tolcher","year":"2017","journal-title":"Cancer Res."},{"issue":"7123","key":"10.1016\/j.bcp.2026.118303_b0845","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","article-title":"A human colon cancer cell capable of initiating tumour growth in immunodeficient mice","volume":"445","author":"O'Brien","year":"2007","journal-title":"Nature"},{"issue":"7123","key":"10.1016\/j.bcp.2026.118303_b0850","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature05384","article-title":"Identification and expansion of human colon-cancer-initiating cells","volume":"445","author":"Ricci-Vitiani","year":"2007","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b0855","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/stem.1233","article-title":"Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells","volume":"30","author":"Kemper","year":"2012","journal-title":"Stem Cells"},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b0860","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1158\/0008-5472.CAN-08-4418","article-title":"Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis","volume":"69","author":"Huang","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118303_b0865","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/cas.16117","article-title":"Cell cycle heterogeneity and plasticity of colorectal cancer stem cells","volume":"115","author":"Higa","year":"2024","journal-title":"Cancer Sci."},{"issue":"14","key":"10.1016\/j.bcp.2026.118303_b0870","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1002\/cam4.2523","article-title":"Cancer-associated fibroblasts secrete Wnt2 to promote cancer progression in colorectal cancer","volume":"8","author":"Aizawa","year":"2019","journal-title":"Cancer Med."},{"issue":"568","key":"10.1016\/j.bcp.2026.118303_b0875","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbrc.2021.06.062","article-title":"Wnt5a in cancer-associated fibroblasts promotes colorectal cancer progression","volume":"3","author":"Hirashima","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0880","doi-asserted-by":"crossref","first-page":"15270","DOI":"10.1038\/s41598-017-15704-y","article-title":"RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations","volume":"7","author":"Fischer","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.02.004","article-title":"MGMT activated by Wnt pathway promotes cisplatin tolerance through inducing slow-cycling cells and nonhomologous end joining in colorectal cancer","volume":"14","author":"Zhang","year":"2024","journal-title":"J. Pharm. Anal."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0890","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41467-019-09898-0","article-title":"MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer","volume":"10","author":"Zhan","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0895","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12964-020-00557-2","article-title":"Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression","volume":"18","author":"Liu","year":"2020","journal-title":"Cell Commun. Signaling"},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b0900","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.molmed.2023.03.006","article-title":"Cells of the tumor microenvironment speak the Wnt language","volume":"29","author":"Katanaev","year":"2023","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b0905","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/ijc.29939","article-title":"CD 90+ stromal cells are the major source of IL\u20106, which supports cancer stem\u2010like cells and inflammation in colorectal cancer","volume":"138","author":"Huynh","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b0910","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/gutjnl-2019-319200","article-title":"STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis","volume":"69","author":"Heichler","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0915","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7150\/jca.121654","article-title":"Interleukin-17 receptor a drives cancer stem-like properties in colorectal cancer through STAT3 activation","volume":"17","author":"Jiang","year":"2026","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0920","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1476-4598-11-87","article-title":"IL-1\u03b2 promotes stemness and invasiveness of colon cancer cells through Zeb1 activation","volume":"11","author":"Li","year":"2012","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.118303_b0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113252","article-title":"The presentation and regulation of the IL-8 network in the epithelial cancer stem-like cell niche in patients with colorectal cancer","volume":"152","author":"Cui","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118303_b0930","article-title":"An IL-6-induced STAT3-to-PI3K signaling switch potently drives PD-L1 transcription in cancer stem cells of colorectal cancer","author":"Tian","year":"2025","journal-title":"Science Bulletin"},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0935","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3892\/ijo.2015.2851","article-title":"The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells","volume":"46","author":"Ying","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0940","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2468-1253(18)30009-8","article-title":"Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial","volume":"3","author":"Jonker","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0945","doi-asserted-by":"crossref","first-page":"42226","DOI":"10.1038\/srep42226","article-title":"CXCL12\/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer","volume":"7","author":"Yu","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0950","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-019-1019-x","article-title":"CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer","volume":"18","author":"Hu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.bcp.2026.118303_b0955","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1186\/s12885-015-1863-z","article-title":"High infiltration of mast cells positive to tryptase predicts worse outcome following resection of colorectal liver metastases","volume":"4","author":"Suzuki","year":"2015","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b0960","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/ijc.31613","article-title":"Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer","volume":"143","author":"Mao","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b0965","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ijc.31099","article-title":"Tumor-infiltrating tryptase(+) mast cells predict unfavorable clinical outcome in solid tumors","volume":"142","author":"Hu","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b0970","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13578-023-01144-x","article-title":"Single-cell analysis unveils activation of mast cells in colorectal cancer microenvironment","volume":"13","author":"Xie","year":"2023","journal-title":"Cell Biosci."},{"issue":"45","key":"10.1016\/j.bcp.2026.118303_b0975","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1038\/s41388-025-03589-5","article-title":"Mast cells interact directly with colorectal cancer cells to promote epithelial-to-mesenchymal transition","volume":"44","author":"Lanzloth","year":"2025","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.bcp.2026.118303_b0980","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004653","article-title":"Mast cell-T cell axis alters development of colitis-dependent and colitis-independent colorectal tumours: potential for therapeutically targeting via mast cell inhibition","volume":"10","author":"Sakita","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b0985","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2015.05.014","article-title":"Activation of mucosal mast cells promotes inflammation-related colon cancer development through recruiting and modulating inflammatory CD11b(+)Gr1(+) cells","volume":"364","author":"Xu","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118303_b0990","doi-asserted-by":"crossref","unstructured":"A. Chaplin, R.M. Rodriguez, J.J. Segura-Sampedro, et al., Insights behind the relationship between colorectal cancer and obesity: is visceral adipose tissue the missing link? Int. J. Mol. Sci., 2022 Oct 28; 23(21).","DOI":"10.3390\/ijms232113128"},{"issue":"15","key":"10.1016\/j.bcp.2026.118303_b0995","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.3390\/ijms25158352","article-title":"The role of adipocytes recruited as part of tumor microenvironment in promoting colorectal cancer metastases","volume":"25","author":"Ma","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b1000","doi-asserted-by":"crossref","first-page":"e2593","DOI":"10.1038\/cddis.2017.21","article-title":"Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer","volume":"8","author":"Wen","year":"2017","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12964-025-02569-2","article-title":"Cancer-associated adipocytes promote peritoneal metastasis of colorectal signet ring cell carcinoma via FABP4 induction","volume":"24","author":"Dai","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b1010","first-page":"4220","article-title":"Obesity-associated leptin promotes chemoresistance in colorectal cancer through YAP-dependent AXL upregulation","volume":"11","author":"Chen","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118303_b1015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s11605-011-1627-2","article-title":"Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis, and prognosis in colon cancer","volume":"15","author":"Li","year":"2011","journal-title":"J. Gastrointest. Surg."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b1020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.15537\/smj.2017.3.16245","article-title":"Lymphangiogenesis and colorectal cancer","volume":"38","author":"Huang","year":"2017","journal-title":"Saudi Med. J."},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b1025","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1053\/j.gastro.2015.03.005","article-title":"Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion","volume":"148","author":"Tacconi","year":"2015","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.bcp.2026.118303_b1030","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1158\/0008-5472.CAN-21-0633","article-title":"Lymphatic PD-L1 expression restricts tumor-specific CD8+ T-cell responses","volume":"81","author":"Cousin","year":"2021","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b1035","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1097\/MS9.0000000000000981","article-title":"Bevacizumab side effects and adverse clinical complications in colorectal cancer patients","volume":"85","author":"Minhajat","year":"2023","journal-title":"Ann. Med. Surg."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12876-024-03134-w","article-title":"Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Song","year":"2024","journal-title":"BMC Gastroenterol."},{"issue":"18","key":"10.1016\/j.bcp.2026.118303_b1045","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager Gerald","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b1050","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500120","article-title":"Trifluridine\u2013tipiracil with and without bevacizumab in colorectal cancer","volume":"5","author":"Nusrat","year":"2026","journal-title":"NEJM Evidence"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1055","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1038\/s41467-026-70620-y","article-title":"First-line Nivolumab plus FOLFOXIRI\/Bevacizumab in advanced RAS\/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial","volume":"17","author":"Damato","year":"2026","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1060","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1859732","article-title":"Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations","volume":"10","author":"Grisaru-Tal","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41698-025-00955-0","article-title":"Deep learning-based quantification of eosinophils and lymphocytes shows complementary prognostic effects in colorectal cancer patients","volume":"9","author":"Baumann","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b1070","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2326-6066.CIR-18-0494","article-title":"Activated eosinophils exert antitumorigenic activities in colorectal cancer","volume":"7","author":"Reichman","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bcp.2026.118303_b1075","doi-asserted-by":"crossref","unstructured":"D. Lopez-Perez, B. Prados-Lopez, J. Galvez, et al., Eosinophils in colorectal cancer: emerging insights into anti-tumoral mechanisms and clinical implications. Int. J. Mol. Sci., 2024 Jun 1; 25(11).","DOI":"10.3390\/ijms25116098"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.alit.2020.10.002","article-title":"How to detect eosinophil ETosis (EETosis) and extracellular traps","volume":"70","author":"Fukuchi","year":"2021","journal-title":"Allergol. Int."},{"key":"10.1016\/j.bcp.2026.118303_b1085","doi-asserted-by":"crossref","unstructured":"S. Andreone, F. Spadaro, C. Buccione, et al., IL-33 promotes CD11b\/CD18-mediated adhesion of eosinophils to cancer cells and synapse-polarized degranulation leading to tumor cell killing. Cancers (Basel). 2019 Oct 26; 11(11).","DOI":"10.3390\/cancers11111664"},{"key":"10.1016\/j.bcp.2026.118303_b1090","doi-asserted-by":"crossref","unstructured":"I.C. Arnold, M. Artola-Boran, A. Gurtner, et al., The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. J. Exp. Med., 2020 Dec 7; 217(12).","DOI":"10.1084\/jem.20190706"},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b1095","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jleuko\/qiae063","article-title":"Eosinophils exhibit a unique transcriptional signature and increased sensitivity to IL-3-induced activation in response to colorectal cancer cells","volume":"116","author":"Itan","year":"2024","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b1100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41416-022-02056-2","article-title":"Th2 cells inhibit growth of colon and pancreas cancers by promoting anti-tumorigenic responses from macrophages and eosinophils","volume":"128","author":"Jacenik","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b1105","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s11605-015-2761-z","article-title":"Prognostic value of perineural invasion in colorectal cancer: a meta-analysis","volume":"19","author":"Yang","year":"2015","journal-title":"J. Gastrointest. Surg."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PAS.0000000000000518","article-title":"Perineural invasion is a strong prognostic factor in colorectal cancer: a systematic review","volume":"40","author":"Knijn","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b1115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","article-title":"NCCN guidelines insights: colon cancer, version 2.2018","volume":"16","author":"Benson","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jss.2015.03.101","article-title":"Adjuvant chemotherapy for the perineural invasion of colorectal cancer","volume":"199","author":"Suzuki","year":"2015","journal-title":"J. Surg. Res."},{"issue":"25","key":"10.1016\/j.bcp.2026.118303_b1125","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"MAGEA6 engages a YY1-dependent transcription to dictate perineural invasion in colorectal cancer","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh)."},{"key":"10.1016\/j.bcp.2026.118303_b1130","article-title":"Schwann cells promote the migration and invasion of colorectal cancer cells via the activated NF-\u03baB\/IL-8 axis in the tumor microenvironment","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"issue":"626","key":"10.1016\/j.bcp.2026.118303_b1135","article-title":"Activated Schwann cells promote tumor growth in colon cancer","volume":"28","author":"He","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13046-022-02556-2","article-title":"A reciprocal feedback between colon cancer cells and Schwann cells promotes the proliferation and metastasis of colon cancer","volume":"41","author":"Han","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118303_b1145","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.3390\/ijms23063375","article-title":"Relationship between VEGF family members, their receptors and cell death in the neoplastic transformation of colorectal cancer","volume":"23","author":"Dakowicz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1150","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s12967-024-05391-5","article-title":"Novel hypoxia-and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer","volume":"22","author":"Huang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b1155","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41416-020-0985-5","article-title":"Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia","volume":"123","author":"Craig","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.118303_b1160","first-page":"167","article-title":"Tumour hypoxia in driving genomic instability and tumour evolution","volume":"25","author":"Suvac","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b1165","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/cells14090673","article-title":"The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis","volume":"14","author":"Bakleh","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166894","article-title":"Estrogen receptor \u03b2 affects hypoxia response in colorectal cancer cells","volume":"1870","author":"Raw\u0142uszko-Wieczorek","year":"2024","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"12","key":"10.1016\/j.bcp.2026.118303_b1175","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.neo.2020.10.006","article-title":"Tumor cell endogenous HIF-1\u03b1 activity induces aberrant angiogenesis and interacts with TRAF6 pathway required for colorectal cancer development","volume":"22","author":"Glaus Garzon","year":"2020","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13046-021-02229-6","article-title":"ROS\/PI3K\/Akt and Wnt\/\u03b2-catenin signalings activate HIF-1\u03b1-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer","volume":"41","author":"Dong","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118303_b1185","doi-asserted-by":"crossref","unstructured":"R. Singhal, S.R. Mitta, N.K. Das, et al., HIF-2\u03b1 activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron. J. Clin. Invest., 2021 Jun 15; 131(12).","DOI":"10.1172\/JCI143691"},{"key":"10.1016\/j.bcp.2026.118303_b1190","doi-asserted-by":"crossref","unstructured":"P.J. Dalal, R. Singhal, B. Hu, et al., Targeting HIF-2\u03b1 in colorectal cancer reveals a cholesterol biosynthesis-dependent ferroptotic vulnerability. Cancer Metab. 2026 Feb 12; 14(1).","DOI":"10.1186\/s40170-026-00421-w"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-020-02667-4","article-title":"Hypoxia and the phenomenon of immune exclusion","volume":"19","author":"Pietrobon","year":"2021","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b1200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073735","article-title":"The tumor microenvironment mediates the HIF-1\u03b1\/PD-L1 pathway to promote immune escape in colorectal cancer","volume":"25","author":"Sun","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118303_b1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116427","article-title":"HIF-1\u03b1 mediates immunosuppression and chemoresistance in colorectal cancer by inhibiting CXCL9, \u221210 and \u221211","volume":"173","author":"Su","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b1210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.cmet.2019.11.002","article-title":"Regulation of tumor initiation by the mitochondrial pyruvate carrier","volume":"31","author":"Bensard","year":"2020","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b1215","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41419-022-05111-1","article-title":"Lactate promotes metastasis of normoxic colorectal cancer stem cells through PGC-1\u03b1-mediated oxidative phosphorylation","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis."},{"issue":"598","key":"10.1016\/j.bcp.2026.118303_b1220","article-title":"MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy","volume":"28","author":"Richiardone","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/15548627.2023.2249762","article-title":"Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer","volume":"20","author":"Li","year":"2024","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41419-025-07498-z","article-title":"Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis","volume":"16","author":"Deng","year":"2025","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118303_b1235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41416-019-0642-z","article-title":"Carbonic anhydrase IX and acid transport in cancer","volume":"122","author":"Becker","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b1240","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-18-0657","article-title":"Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically","volume":"7","author":"Chafe","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118303_b1245","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.trecan.2017.05.002","article-title":"Targeting hypoxia-inducible factors for antiangiogenic cancer therapy","volume":"3","author":"Rey","year":"2017","journal-title":"Trends in Cancer."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1250","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13550-019-0543-4","article-title":"Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [(18)F]HX4 PET imaging study in colorectal cancer xenografts","volume":"9","author":"De Bruycker","year":"2019","journal-title":"EJNMMI Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118303_b1255","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.bcp.2026.118303_b1260","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.118303_b1265","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.3390\/biomedicines12102381","article-title":"Insights into CSF-1R expression in the tumor microenvironment","volume":"12","author":"Tomassetti","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118303_b1270","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110207","article-title":"Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8+ T cells showed synergistic effects on improved disease-free survival in treatment-na\u00efve CRC patients","volume":"119","author":"Meyiah","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118303_b1275","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00262-024-03751-0","article-title":"A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab\/ipilimumab plus CD1c (BDCA-1)+\/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors","volume":"73","author":"Vounckx","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1280","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12029-025-01378-7","article-title":"Efficacy of radiotherapy combined with immunotherapy in MSS\/pMMR metastatic colorectal cancer: a propensity-matched retrospective study","volume":"56","author":"Mou","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.bcp.2026.118303_b1285","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"8094","key":"10.1016\/j.bcp.2026.118303_b1290","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41586-025-09679-4","article-title":"Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers","volume":"648","author":"Tan","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2026.118303_b1295","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012466","article-title":"Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study","volume":"14","author":"Perez-Gracia","year":"2026","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118303_b1300","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12672-026-04575-3","article-title":"Biomarker guided combination strategies and perioperative integration for immune cold microsatellite stable colorectal cancer","volume":"17","author":"Yao","year":"2026","journal-title":"Discov. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118303_b1305","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/hep.22795","article-title":"Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization","volume":"49","author":"Von Oppen","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2026.118303_b1310","article-title":"632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI na\u00efve MSS\/MSI-L colorectal cancer (CRC)","volume":"12","author":"Barbu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118303_b1315","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-15371-7","article-title":"CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine\/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer","author":"Passardi","year":"2025","journal-title":"BMC Cancer"},{"issue":"16_suppl","key":"10.1016\/j.bcp.2026.118303_b1320","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e15556","article-title":"IDOV-Safe: an intravenously deliverable oncolytic vaccinia virus for solid tumors refractory to standard of care\u2014preliminary results from the pMMR\/MSS CRC cohort","volume":"43","author":"Xie","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:30:20Z","timestamp":1791909020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":264,"alternative-id":["S0006295226006428"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118303","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering the colorectal tumor microenvironment: Interactions and targets for effective therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118303"}}